Highly efficient ketone body treatment in multiple acyl-CoA dehydrogenase deficiency-related leukodystrophy

Pediatric Research

Volumn 77, Issue 1, 2015, Pages 91-98

  Gautschi, Matthias ^a   Weisstanner, Christian ^a   Slotboom, Johannes ^a   Nava, Esmeralda ^a   Zürcher, Theres ^a   Nuoffer, Jean Marc ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; BACLOFEN; CARNITINE; HYDROXYBUTYRIC ACID; RIBOFLAVIN; SODIUM D L 3 HYDROXYBUTYRATE; UBIQUINONE; UNCLASSIFIED DRUG; FAT INTAKE; KETONE; UBIDECARENONE;

ARTICLE; CASE REPORT; CHILD; DRUG TOLERABILITY; DYSTONIA; HUMAN; LEUKODYSTROPHY; MALE; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SOCIAL INTERACTION; SPECTROSCOPY; SPEECH; ANALOGS AND DERIVATIVES; BRAIN; CHEMISTRY; COMA; COMPLICATION; CONSANGUINITY; DEMYELINATING DISEASE; FAT INTAKE; HYPOGLYCEMIA; METABOLISM; MUSCLE WEAKNESS; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

BRAIN; CARNITINE; CHILD, PRESCHOOL; COMA; CONSANGUINITY; DIETARY FATS; HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES; HUMANS; HYPOGLYCEMIA; KETONES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE ACYL COENZYME A DEHYDROGENASE DEFICIENCY; MUSCLE WEAKNESS; RIBOFLAVIN; TREATMENT OUTCOME; UBIQUINONE;

EID: 84927939764     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2014.154     Document Type: Article

References (33)

1. Frerman F, Goodman SI. Defects of electron transfer flavoprotein and electron transfer flavoprotein-ubiquinone oxidoreductase: glutaric acidemia type II. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001:2357-65
2. Dusheiko G, Kew MC, Joffe BI, Lewin JR, Mantagos S, Tanaka K. Recurrent hypoglycemia associated with glutaric aciduria type II in an adult. N Engl J Med 1979;301:1405-9
3. Bell RB, Brownell AK, Roe CR, et al. Electron transfer flavoprotein: ubiquinone oxidoreductase (ETF:QO) deficiency in an adult. Neurology 1990;40:1779-82
4. Pollard LM, Williams NR, Espinoza L, et al. Diagnosis, treatment, and long-term outcomes of late-onset (type III) multiple acyl-CoA dehydrogenase deficiency. J Child Neurol 2010;25:954-60
5. Wolfe LA, He M, Vockley J, et al. Novel ETF dehydrogenase mutations in a patient with mild glutaric aciduria type II and complex II-III deficiency in liver and muscle. J Inherit Metab Dis 2010;33:Suppl 3:S481-7
6. Lee HC, Lai CK, Siu TS, et al. Role of postmortem genetic testing demonstrated in a case of glutaric aciduria type II. Diagn Mol Pathol 2010;19:184-6
7. Niederwieser A, Steinmann B, Exner U, et al. Multiple acyl-Co A dehydrogenation deficiency (MADD) in a boy with nonketotic hypoglycemia, hepatomegaly, muscle hypotonia and cardiomyopathy. Detection of N-isovalerylglutamic acid and its monoamide. Helv Paediatr Acta 1983;38:9-26
8. Ramos Fernandez JM, Martinez-Pardo M, Garcia Villanueva M, et al. Miopatia lipidica por aciduria glutarica tipo II sensible a riboflavina. An Esp Pediatr 1995;42:207-10
9. Uziel G, Garavaglia B, Ciceri E, Moroni I, Rimoldi M. Riboflavin-responsive glutaric aciduria type II presenting as a leukodystrophy. Pediatr Neurol 1995;13:333-5
10. Bonham JR, Tanner MS, Pollitt RJ, et al. Oral sodium 3-hydroxybutyrate, a novel adjunct to treatment for multiple acyl CoA dehydrogenase deficiency. J Inherit Metab Dis 1999;22:101
11. Plecko B, Stoeckler-Ipsiroglu S, Schober E, et al. Oral beta-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of beta-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy. Pediatr Res 2002;52:301-6
12. Valayannopoulos V, Bajolle F, Arnoux JB, et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res 2011;70:638-41
13. Van Hove JL, Grunewald S, Jaeken J, et al. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet 2003;361:1433-5
14. Vassault A. Lactate, pyruvate, acetoacetate and 3-hydroxybutyrate. In: Blau N, Duran N, Gibson KM, eds. Laboratory Guide to the Methods in Biochemical Genetics. Berlin, Germany: Springer-Verlag, 2008:35-51
15. Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids 2004;70:243-51
16. Soeters MR, Serlie MJ, Sauerwein HP, et al. Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite. Metab Clin Exp 2012;61:966-73
17. Reed WD, Ozand PT. Enzymes of L-(+)-3-hydroxybutyrate metabolism in the rat. Arch Biochem Biophys 1980;205:94-103
18. Swiatek KR, Dombrowski GJ Jr, Chao KL. The metabolism of Dand L-3-hydroxybutyrate in developing rat brain. Biochem Med 1984;31:332-46
19. Tsai YC, Chou YC, Wu AB, et al. Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes. Life Sci 2006;78:1385-91
20. Lincoln BC, Des Rosiers C, Brunengraber H. Metabolism of S-3-hydroxybutyrate in the perfused rat liver. Arch Biochem Biophys 1987;259:149-56
21. Edmond J. Ketone bodies as precursors of sterols and fatty acids in the developing rat. J Biol Chem 1974;249:72-80
22. Olsen RK, Pourfarzam M, Morris AA, et al. Lipid-storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with lateonset multiple acyl-CoA dehydrogenation deficiency. J Inherit Metab Dis 2004;27:671-8
23. al-Essa MA, Rashed MS, Bakheet SM, Patay ZJ, Ozand PT. Glutaric aciduria type II: observations in seven patients with neonatal-and late-onset disease. J Perinatol 2000;20:120-8
24. Goodman SI, Stene DO, McCabe ER, et al. Glutaric acidemia type II: clinical, biochemical, and morphologic considerations. J Pediatr 1982;100:946-50
25. Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab 2008;93:36-9
26. Singla M, Guzman G, Griffin AJ, Bharati S. Cardiomyopathy in multiple Acyl-CoA dehydrogenase deficiency: A clinico-pathological correlation and review of literature. Pediatr Cardiol 2008;29:446-51
27. Tamaoki Y, Kimura M, Hasegawa Y, Iga M, Inoue M, Yamaguchi S. A survey of Japanese patients with mitochondrial fatty acid beta-oxidation and related disorders as detected from 1985 to 2000. Brain Dev 2002;24:675-80
28. Ho VB, Fitz CR, Chuang SH, Geyer CA. Bilateral basal ganglia lesions: pediatric differential considerations. Radiographics 1993;13:269-92
29. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9
30. Kehrer C, Blumenstock G, Raabe C, Krageloh-Mann I. Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy. Dev Med Child Neurol 2011;53:156-60
31. Eliasson AC, Krumlinde-Sundholm L, Rosblad B, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 2006;48:549-54
32. Scheidegger O, Wingeier K, Stefan D, et al. Optimized quantitative magnetic resonance spectroscopy for clinical routine. Magn Reson Med 2013;70:25-32
33. Bergmeyer HU. 3-hydroxybutyrate dehydrogenase. In: Bergmeyer HU, Bergmeyer J, Grassl M, eds. Methods of Enzymatic Analysis. 3rd ed. Weinheim, Germany: Verlag Chemie, 1983:226-8.